ID   ITCH_HUMAN              Reviewed;         903 AA.
AC   Q96J02; A6NEW4; B4E234; E1P5P3; F5H217; O43584; Q5QP37; Q5TEL0;
AC   Q96F66; Q9BY75; Q9H451; Q9H4U5;
DT   03-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2003, sequence version 2.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=E3 ubiquitin-protein ligase Itchy homolog;
DE            Short=Itch;
DE            EC=2.3.2.26;
DE   AltName: Full=Atrophin-1-interacting protein 4;
DE            Short=AIP4;
DE   AltName: Full=HECT-type E3 ubiquitin transferase Itchy homolog;
DE   AltName: Full=NFE2-associated polypeptide 1;
DE            Short=NAPP1;
GN   Name=ITCH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INTERACTION WITH NFE2.
RC   TISSUE=Leukemia;
RX   PubMed=11318614; DOI=10.1006/geno.2001.6512;
RA   Chen X., Wen S.-C., Fukuda M.N., Gavva N.R., Hsu D.-W., Akama T.O.,
RA   Yang-Peng T.L., Shen C.K.J.;
RT   "Human ITCH is a co-regulator of the hematopoietic transcription
RT   factor NF-E2.";
RL   Genomics 73:238-241(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Miyazaki K., Okamoto Y., Sakamoto M., Nakagawara A.;
RT   "Homo sapiens mRNA for ubiquitin protein ligase Itch, complete cds.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 83-903 (ISOFORM 2), AND INTERACTION WITH
RP   ATN1.
RC   TISSUE=Fetal brain;
RX   PubMed=9647693; DOI=10.1006/mcne.1998.0677;
RA   Wood J.D., Yuan J., Margolis R.L., Colomer V., Duan K., Kushi J.,
RA   Kaminsky Z., Kleiderlein J.J. Jr., Sharp A.H., Ross C.A.;
RT   "Atrophin-1, the DRPLA gene product, interacts with two families of WW
RT   domain-containing proteins.";
RL   Mol. Cell. Neurosci. 11:149-160(1998).
RN   [8]
RP   PROTEIN SEQUENCE OF 463-470; 503-510; 514-526; 644-665 AND 875-881,
RP   INTERACTION WITH LMP2A, AND MUTAGENESIS OF CYS-871.
RC   TISSUE=B-cell;
RX   PubMed=11046148; DOI=10.1128/MCB.20.22.8526-8535.2000;
RA   Winberg G., Matskova L., Chen F., Plant P., Rotin D., Gish G.,
RA   Ingham R., Ernberg I., Pawson T.;
RT   "Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3
RT   protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases.";
RL   Mol. Cell. Biol. 20:8526-8535(2000).
RN   [9]
RP   INTERACTION WITH CBLC, AND PHOSPHORYLATION.
RX   PubMed=12226085; DOI=10.1074/jbc.M206460200;
RA   Courbard J.-R., Fiore F., Adelaide J., Borg J.P., Birnbaum D.,
RA   Ollendorff V.;
RT   "Interaction between two ubiquitin-protein isopeptide ligases of
RT   different classes, CBLC and AIP4/ITCH.";
RL   J. Biol. Chem. 277:45267-45275(2002).
RN   [10]
RP   INTERACTION WITH RNF11.
RX   PubMed=14559117; DOI=10.1016/j.bbadis.2003.07.001;
RA   Kitching R., Wong M.J., Koehler D., Burger A.M., Landberg G., Gish G.,
RA   Seth A.K.;
RT   "The RING-H2 protein RNF11 is differentially expressed in breast
RT   tumours and interacts with HECT-type E3 ligases.";
RL   Biochim. Biophys. Acta 1639:104-112(2003).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-871.
RX   PubMed=14602072; DOI=10.1016/S1534-5807(03)00321-6;
RA   Marchese A., Raiborg C., Santini F., Keen J.H., Stenmark H.,
RA   Benovic J.L.;
RT   "The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of
RT   the G protein-coupled receptor CXCR4.";
RL   Dev. Cell 5:709-722(2003).
RN   [12]
RP   PHOSPHORYLATION AT THR-385 AND SER-450, AND INTERACTION WITH SGK3.
RX   PubMed=16888620; DOI=10.1038/sj.emboj.7601267;
RA   Slagsvold T., Marchese A., Brech A., Stenmark H.;
RT   "CISK attenuates degradation of the chemokine receptor CXCR4 via the
RT   ubiquitin ligase AIP4.";
RL   EMBO J. 25:3738-3749(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH DTX1, AND UBIQUITINATION OF DTX1.
RX   PubMed=17028573; DOI=10.1038/sj.embor.7400822;
RA   Chastagner P., Israel A., Brou C.;
RT   "Itch/AIP4 mediates Deltex degradation through the formation of K29-
RT   linked polyubiquitin chains.";
RL   EMBO Rep. 7:1147-1153(2006).
RN   [14]
RP   PHOSPHORYLATION AT TYR-420, INTERACTION WITH JUNB AND FYN, FUNCTION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF TYR-343;
RP   TYR-420 AND TYR-455.
RX   PubMed=16387660; DOI=10.1016/j.molcel.2005.11.014;
RA   Yang C., Zhou W., Jeon M.S., Demydenko D., Harada Y., Zhou H.,
RA   Liu Y.C.;
RT   "Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated
RT   tyrosine phosphorylation.";
RL   Mol. Cell 21:135-141(2006).
RN   [15]
RP   INTERACTION WITH NFE2, AND FUNCTION.
RX   PubMed=18718448; DOI=10.1016/j.bbrc.2008.07.164;
RA   Lee T.-L., Shyu Y.-C., Hsu T.-Y., Shen C.-K.J.;
RT   "Itch regulates p45/NF-E2 in vivo by Lys63-linked ubiquitination.";
RL   Biochem. Biophys. Res. Commun. 375:326-330(2008).
RN   [16]
RP   AUTOUBIQUITINATION, FUNCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18718449; DOI=10.1016/j.bcp.2008.07.028;
RA   Scialpi F., Malatesta M., Peschiaroli A., Rossi M., Melino G.,
RA   Bernassola F.;
RT   "Itch self-polyubiquitylation occurs through lysine-63 linkages.";
RL   Biochem. Pharmacol. 76:1515-1521(2008).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18819914; DOI=10.1074/jbc.M804120200;
RA   Putz U., Howitt J., Lackovic J., Foot N., Kumar S., Silke J.,
RA   Tan S.S.;
RT   "Nedd4 family-interacting protein 1 (Ndfip1) is required for the
RT   exosomal secretion of Nedd4 family proteins.";
RL   J. Biol. Chem. 283:32621-32627(2008).
RN   [18]
RP   FUNCTION, AND UBIQUITINATION OF NOTCH1.
RX   PubMed=18628966; DOI=10.1371/journal.pone.0002735;
RA   Chastagner P., Israel A., Brou C.;
RT   "AIP4/Itch regulates Notch receptor degradation in the absence of
RT   ligand.";
RL   PLoS ONE 3:E2735-E2735(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   INTERACTION WITH SPG20.
RX   PubMed=19580544; DOI=10.1042/BJ20082398;
RA   Edwards T.L., Clowes V.E., Tsang H.T., Connell J.W., Sanderson C.M.,
RA   Luzio J.P., Reid E.;
RT   "Endogenous spartin (SPG20) is recruited to endosomes and lipid
RT   droplets and interacts with the ubiquitin E3 ligases AIP4 and AIP5.";
RL   Biochem. J. 423:31-39(2009).
RN   [21]
RP   FUNCTION, AND UBIQUITINATION OF RIPK2.
RX   PubMed=19592251; DOI=10.1016/j.cub.2009.06.038;
RA   Tao M., Scacheri P.C., Marinis J.M., Harhaj E.W., Matesic L.E.,
RA   Abbott D.W.;
RT   "ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence
RT   inflammatory signaling pathways.";
RL   Curr. Biol. 19:1255-1263(2009).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH RNF11.
RX   PubMed=19131965; DOI=10.1038/emboj.2008.285;
RA   Shembade N., Parvatiyar K., Harhaj N.S., Harhaj E.W.;
RT   "The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-
RT   kappaB signalling.";
RL   EMBO J. 28:513-522(2009).
RN   [23]
RP   INTERACTION WITH CXCR4.
RX   PubMed=19116316; DOI=10.1091/mbc.E08-03-0308;
RA   Bhandari D., Robia S.L., Marchese A.;
RT   "The E3 ubiquitin ligase atrophin interacting protein 4 binds directly
RT   to the chemokine receptor CXCR4 via a novel WW domain-mediated
RT   interaction.";
RL   Mol. Biol. Cell 20:1324-1339(2009).
RN   [24]
RP   FUNCTION, UBIQUITINATION OF MAVS, INTERACTION WITH PCBP2, AND
RP   MUTAGENESIS OF CYS-871.
RX   PubMed=19881509; DOI=10.1038/ni.1815;
RA   You F., Sun H., Zhou X., Sun W., Liang S., Zhai Z., Jiang Z.;
RT   "PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin
RT   ligase AIP4.";
RL   Nat. Immunol. 10:1300-1308(2009).
RN   [25]
RP   INVOLVEMENT IN ADMFD.
RX   PubMed=20170897; DOI=10.1016/j.ajhg.2010.01.028;
RA   Lohr N.J., Molleston J.P., Strauss K.A., Torres-Martinez W.,
RA   Sherman E.A., Squires R.H., Rider N.L., Chikwava K.R., Cummings O.W.,
RA   Morton D.H., Puffenberger E.G.;
RT   "Human ITCH E3 ubiquitin ligase deficiency causes syndromic
RT   multisystem autoimmune disease.";
RL   Am. J. Hum. Genet. 86:447-453(2010).
RN   [26]
RP   INTERACTION WITH SNX9 AND SNX18, AND UBIQUITINATION OF SNX9.
RX   PubMed=20491914; DOI=10.1111/j.1742-4658.2010.07698.x;
RA   Baumann C., Lindholm C.K., Rimoldi D., Levy F.;
RT   "The E3 ubiquitin ligase Itch regulates sorting nexin 9 through an
RT   unconventional substrate recognition domain.";
RL   FEBS J. 277:2803-2814(2010).
RN   [27]
RP   FUNCTION, INTERACTION WITH P15 BID, AND UBIQUITINATION OF P15 BID.
RX   PubMed=20392206; DOI=10.1111/j.1742-4658.2010.07562.x;
RA   Azakir B.A., Desrochers G., Angers A.;
RT   "The ubiquitin ligase Itch mediates the antiapoptotic activity of
RT   epidermal growth factor by promoting the ubiquitylation and
RT   degradation of the truncated C-terminal portion of Bid.";
RL   FEBS J. 277:1319-1330(2010).
RN   [28]
RP   FUNCTION, INTERACTION WITH TXNIP, AND UBIQUITINATION OF TXNIP.
RX   PubMed=20068034; DOI=10.1074/jbc.M109.063321;
RA   Zhang P., Wang C., Gao K., Wang D., Mao J., An J., Xu C., Wu D.,
RA   Yu H., Liu J.O., Yu L.;
RT   "The ubiquitin ligase itch regulates apoptosis by targeting
RT   thioredoxin-interacting protein for ubiquitin-dependent degradation.";
RL   J. Biol. Chem. 285:8869-8879(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH ERBB4, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   INTERACTION WITH PI4K2A, AND FUNCTION.
RX   PubMed=23146885; DOI=10.1038/embor.2012.164;
RA   Mossinger J., Wieffer M., Krause E., Freund C., Gerth F., Krauss M.,
RA   Haucke V.;
RT   "Phosphatidylinositol 4-kinase IIalpha function at endosomes is
RT   regulated by the ubiquitin ligase Itch.";
RL   EMBO Rep. 13:1087-1094(2012).
RN   [32]
RP   INTERACTION WITH OTUD7B.
RX   PubMed=22179831; DOI=10.1038/onc.2011.587;
RA   Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F.,
RA   Aulmann S., Ben-Chetrit N., Pines G., Navon R., Crosetto N.,
RA   Kostler W., Carvalho S., Lavi S., Schmitt F., Dikic I., Yakhini Z.,
RA   Sinn P., Mills G.B., Yarden Y.;
RT   "Deubiquitination of EGFR by Cezanne-1 contributes to cancer
RT   progression.";
RL   Oncogene 31:4599-4608(2012).
RN   [33]
RP   INTERACTION WITH ARRDC4.
RX   PubMed=23236378; DOI=10.1371/journal.pone.0050557;
RA   Shea F.F., Rowell J.L., Li Y., Chang T.H., Alvarez C.E.;
RT   "Mammalian alpha arrestins link activated seven transmembrane
RT   receptors to Nedd4 family e3 ubiquitin ligases and interact with beta
RT   arrestins.";
RL   PLoS ONE 7:E50557-E50557(2012).
RN   [34]
RP   FUNCTION IN UBIQUITINATION OF BRAT1.
RX   PubMed=25631046; DOI=10.1074/jbc.M114.613687;
RA   Low L.H., Chow Y.L., Li Y., Goh C.P., Putz U., Silke J., Ouchi T.,
RA   Howitt J., Tan S.S.;
RT   "Nedd4 family interacting protein 1 (Ndfip1) is required for
RT   ubiquitination and nuclear trafficking of BRCA1-associated ATM
RT   activator 1 (BRAT1) during the DNA damage response.";
RL   J. Biol. Chem. 290:7141-7150(2015).
RN   [35]
RP   INTERACTION WITH UBE2L3.
RX   PubMed=25632008; DOI=10.4049/jimmunol.1402742;
RA   Kathania M., Zeng M., Yadav V.N., Moghaddam S.J., Yang B.,
RA   Venuprasad K.;
RT   "Ndfip1 regulates itch ligase activity and airway inflammation via
RT   UbcH7.";
RL   J. Immunol. 194:2160-2167(2015).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 246-270 IN COMPLEX WITH
RP   ARHGEF7.
RX   PubMed=17652093; DOI=10.1074/jbc.M702678200;
RA   Janz J.M., Sakmar T.P., Min K.C.;
RT   "A novel interaction between atrophin-interacting protein 4 and beta-
RT   p21-activated kinase-interactive exchange factor is mediated by an SH3
RT   domain.";
RL   J. Biol. Chem. 282:28893-28903(2007).
RN   [37]
RP   STRUCTURE BY NMR OF 328-357.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second WW domain of ITCHY homolog E3
RT   ubiquitin protein ligase (ITCH).";
RL   Submitted (OCT-2006) to the PDB data bank.
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase which accepts
CC       ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a
CC       thioester and then directly transfers the ubiquitin to targeted
CC       substrates. It catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked
CC       ubiquitin conjugation. It is involved in the control of
CC       inflammatory signaling pathways. Is an essential component of a
CC       ubiquitin-editing protein complex, comprising also TNFAIP3,
CC       TAX1BP1 and RNF11, that ensures the transient nature of
CC       inflammatory signaling pathways. Promotes the association of the
CC       complex after TNF stimulation. Once the complex is formed, TNFAIP3
CC       deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and
CC       catalyzes the formation of 'Lys-48'-polyubiquitin chains. This
CC       leads to RIPK1 proteasomal degradation and consequently
CC       termination of the TNF- or LPS-mediated activation of NFKB1.
CC       Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences
CC       NOD2-dependent signal transduction pathways. Regulates the
CC       transcriptional activity of several transcription factors, and
CC       probably plays an important role in the regulation of immune
CC       response. Ubiquitinates NFE2 by 'Lys-63' linkages and is
CC       implicated in the control of the development of hematopoietic
CC       lineages. Critical regulator of T-helper (TH2) cytokine
CC       development through its ability to induce JUNB ubiquitination and
CC       degradation (By similarity). Ubiquitinates SNX9. Ubiquitinates
CC       CXCR4 and HGS/HRS and regulates sorting of CXCR4 to the
CC       degradative pathway. It is involved in the negative regulation of
CC       MAVS-dependent cellular antiviral responses. Ubiquitinates MAVS
CC       through 'Lys-48'-linked conjugation resulting in MAVS proteasomal
CC       degradation. Ubiquitinates MAP3K7 through 'Lys-48'-linked
CC       conjugation (By similarity). Involved in the regulation of
CC       apoptosis and reactive oxygen species levels through the
CC       ubiquitination and proteasomal degradation of TXNIP. Mediates the
CC       antiapoptotic activity of epidermal growth factor through the
CC       ubiquitination and proteasomal degradation of p15 BID. Targets
CC       DTX1 for lysosomal degradation and controls NOTCH1 degradation, in
CC       the absence of ligand, through 'Lys-29'-linked polyubiquitination.
CC       Ubiquitinates BRAT1 and this ubiquitination is enhanced in the
CC       presence of NDFIP1 (PubMed:25631046).
CC       {ECO:0000250|UniProtKB:Q8C863, ECO:0000269|PubMed:14602072,
CC       ECO:0000269|PubMed:16387660, ECO:0000269|PubMed:17028573,
CC       ECO:0000269|PubMed:18628966, ECO:0000269|PubMed:18718448,
CC       ECO:0000269|PubMed:18718449, ECO:0000269|PubMed:19131965,
CC       ECO:0000269|PubMed:19592251, ECO:0000269|PubMed:19881509,
CC       ECO:0000269|PubMed:20068034, ECO:0000269|PubMed:20392206,
CC       ECO:0000269|PubMed:23146885, ECO:0000269|PubMed:25631046}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- ENZYME REGULATION: Activated by NDFIP1- and NDFIP2-binding.
CC       {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:17028573, ECO:0000269|PubMed:18718448,
CC       ECO:0000269|PubMed:19592251, ECO:0000269|PubMed:19881509,
CC       ECO:0000269|PubMed:23146885}.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts (via its WW domains)
CC       with OCNL, NOTCH1 AND JUN. Interacts (via WW domain 2) with N4BP1;
CC       leading to inhibiting its E3 ubiquitin-protein ligase activity.
CC       Interacts with JUNB; the interaction promotes ITCH-mediated
CC       ubiquitination and degradation of JUNB. Interacts with NDFIP1 and
CC       NDFIP2; this interaction activates the E3 ubiquitin-protein ligase
CC       and may induce its recruitment to exosomes (By similarity).
CC       Interacts with ARHGEF7 (PubMed:17652093). Interacts with RNF11.
CC       Interacts (via the WW 1 domain) with NFE2 (via the PXY motif 1);
CC       the interaction promotes 'Lys-63'-linked ubiquitination of NFE2,
CC       retains it in the cytoplasm and prevents its transactivation
CC       activity. Interacts with FYN; the interaction phosphorylates ITCH
CC       on Tyr-420 decreasing binding of JUNB. Interacts (via WW domains)
CC       with CXCR4 (via C-terminus); the interaction depends on CXCR4
CC       phosphorylation. Interacts (via WW domains) with PCBP2 within a
CC       complex containing ITCH, MAVS and PCBP2. Interacts (via WW
CC       domains) with TXNIP (via C-terminus). Interacts with p15 BID.
CC       Interacts with ERBB4, DTX1, SPG20, SNX9 and SNX18. Interacts (via
CC       its WW domains) with ATN1. Interacts with Epstein-Barr virus
CC       LMP2A. Interacts (via WW domains) with SGK3. Interacts with
CC       OTUD7B. Interacts with PI4K2A (PubMed:23146885). Interacts with
CC       ARRDC4 (PubMed:23236378). Part of a complex containing ITCH,
CC       NDFIP1 and MAP3K7 (By similarity). Interacts with UBE2L3; the
CC       interaction is mediated by NDFIP1 (PubMed:25632008).
CC       {ECO:0000250|UniProtKB:Q8C863, ECO:0000269|PubMed:11046148,
CC       ECO:0000269|PubMed:11318614, ECO:0000269|PubMed:12226085,
CC       ECO:0000269|PubMed:14559117, ECO:0000269|PubMed:16387660,
CC       ECO:0000269|PubMed:16888620, ECO:0000269|PubMed:17028573,
CC       ECO:0000269|PubMed:17652093, ECO:0000269|PubMed:18718448,
CC       ECO:0000269|PubMed:19116316, ECO:0000269|PubMed:19131965,
CC       ECO:0000269|PubMed:19580544, ECO:0000269|PubMed:19881509,
CC       ECO:0000269|PubMed:20068034, ECO:0000269|PubMed:20392206,
CC       ECO:0000269|PubMed:20491914, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:22179831, ECO:0000269|PubMed:23146885,
CC       ECO:0000269|PubMed:23236378, ECO:0000269|PubMed:25632008,
CC       ECO:0000269|PubMed:9647693}.
CC   -!- INTERACTION:
CC       P70444:Bid (xeno); NbExp=2; IntAct=EBI-1564678, EBI-783400;
CC       Q9NQC7:CYLD; NbExp=3; IntAct=EBI-1564678, EBI-2117940;
CC       P08151:GLI1; NbExp=4; IntAct=EBI-1564678, EBI-308084;
CC       P13285:LMP2 (xeno); NbExp=3; IntAct=EBI-1564678, EBI-7181113;
CC       Q9QZS3-2:Numb (xeno); NbExp=2; IntAct=EBI-1564678, EBI-3896014;
CC       Q9BTU6:PI4K2A; NbExp=5; IntAct=EBI-1564678, EBI-3239392;
CC       Q9Y3C5:RNF11; NbExp=2; IntAct=EBI-1564678, EBI-396669;
CC       Q96BR1:SGK3; NbExp=5; IntAct=EBI-1564678, EBI-2801236;
CC       Q9Y5X1:SNX9; NbExp=7; IntAct=EBI-1564678, EBI-77848;
CC       Q13625:TP53BP2; NbExp=2; IntAct=EBI-1564678, EBI-77642;
CC       O15350-1:TP73; NbExp=5; IntAct=EBI-1564678, EBI-389619;
CC       O15350-8:TP73; NbExp=2; IntAct=EBI-1564678, EBI-5651259;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Cytoplasm {ECO:0000250}.
CC       Nucleus. Note=Associates with endocytic vesicles. May be recruited
CC       to exosomes by NDFIP1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96J02-1; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=2;
CC         IsoId=Q96J02-2; Sequence=VSP_008451;
CC       Name=3;
CC         IsoId=Q96J02-3; Sequence=VSP_044732, VSP_008451;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: On T-cell activation, phosphorylation by the JNK cascade on
CC       serine and threonine residues surrounding the PRR domain
CC       accelerates the ubiquitination and degradation of JUN and JUNB.
CC       The increased ITCH catalytic activity due to phosphorylation by
CC       JNK1 may occur due to a conformational change disrupting the
CC       interaction between the PRR/WW motifs domain and the HECT domain
CC       and, thus exposing the HECT domain (By similarity).
CC       Phosphorylation by FYN reduces interaction with JUNB and
CC       negatively controls JUN ubiquitination and degradation.
CC       {ECO:0000250, ECO:0000269|PubMed:12226085,
CC       ECO:0000269|PubMed:16387660, ECO:0000269|PubMed:16888620,
CC       ECO:0000269|PubMed:18718449}.
CC   -!- PTM: Ubiquitinated; autopolyubiquitination with 'Lys-63' linkages
CC       which does not lead to protein degradation.
CC       {ECO:0000269|PubMed:18718449}.
CC   -!- DISEASE: Autoimmune disease, multisystem, with facial dysmorphism
CC       (ADMFD) [MIM:613385]: A disorder characterized by organomegaly,
CC       failure to thrive, developmental delay, dysmorphic features and
CC       autoimmune inflammatory cell infiltration of the lungs, liver and
CC       gut. {ECO:0000269|PubMed:20170897}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF095745; AAK39399.1; -; mRNA.
DR   EMBL; AB056663; BAB39389.1; -; mRNA.
DR   EMBL; AK304090; BAG64996.1; -; mRNA.
DR   EMBL; AK315212; BAG37647.1; -; mRNA.
DR   EMBL; AL109923; CAI21458.1; -; Genomic_DNA.
DR   EMBL; AL356299; CAI21458.1; JOINED; Genomic_DNA.
DR   EMBL; AL356299; CAI17959.1; -; Genomic_DNA.
DR   EMBL; AL109923; CAI17959.1; JOINED; Genomic_DNA.
DR   EMBL; AL356299; CAI17960.1; -; Genomic_DNA.
DR   EMBL; AL109923; CAI17960.1; JOINED; Genomic_DNA.
DR   EMBL; AL109923; CAI21459.1; -; Genomic_DNA.
DR   EMBL; AL356299; CAI21459.1; JOINED; Genomic_DNA.
DR   EMBL; CH471077; EAW76272.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76274.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76276.1; -; Genomic_DNA.
DR   EMBL; BC006848; AAH06848.1; -; mRNA.
DR   EMBL; BC011571; AAH11571.1; -; mRNA.
DR   EMBL; AF038564; AAC04845.1; -; mRNA.
DR   CCDS; CCDS13234.1; -. [Q96J02-2]
DR   CCDS; CCDS58768.1; -. [Q96J02-1]
DR   CCDS; CCDS58769.1; -. [Q96J02-3]
DR   RefSeq; NP_001244066.1; NM_001257137.2. [Q96J02-1]
DR   RefSeq; NP_001244067.1; NM_001257138.2. [Q96J02-3]
DR   RefSeq; NP_001311126.1; NM_001324197.1. [Q96J02-1]
DR   RefSeq; NP_001311127.1; NM_001324198.1. [Q96J02-2]
DR   RefSeq; NP_113671.3; NM_031483.6. [Q96J02-2]
DR   RefSeq; XP_016883578.1; XM_017028089.1. [Q96J02-1]
DR   RefSeq; XP_016883580.1; XM_017028091.1. [Q96J02-3]
DR   UniGene; Hs.632272; -.
DR   PDB; 2DMV; NMR; -; A=328-357.
DR   PDB; 2KYK; NMR; -; A=359-392.
DR   PDB; 2NQ3; X-ray; 1.80 A; A=1-155.
DR   PDB; 2P4R; X-ray; 2.00 A; T=246-270.
DR   PDB; 2YSF; NMR; -; A=480-512.
DR   PDB; 3TUG; X-ray; 2.27 A; A=524-903.
DR   PDB; 4ROF; X-ray; 2.03 A; A/B=436-474.
DR   PDB; 5C7M; X-ray; 3.03 A; A=524-899.
DR   PDB; 5CQ2; X-ray; 1.40 A; A=433-521.
DR   PDB; 5DWS; X-ray; 1.65 A; A/C/E/G=436-474.
DR   PDB; 5DZD; X-ray; 1.57 A; A/B=475-514.
DR   PDB; 5SXP; X-ray; 1.65 A; F/G=249-269.
DR   PDBsum; 2DMV; -.
DR   PDBsum; 2KYK; -.
DR   PDBsum; 2NQ3; -.
DR   PDBsum; 2P4R; -.
DR   PDBsum; 2YSF; -.
DR   PDBsum; 3TUG; -.
DR   PDBsum; 4ROF; -.
DR   PDBsum; 5C7M; -.
DR   PDBsum; 5CQ2; -.
DR   PDBsum; 5DWS; -.
DR   PDBsum; 5DZD; -.
DR   PDBsum; 5SXP; -.
DR   ProteinModelPortal; Q96J02; -.
DR   SMR; Q96J02; -.
DR   BioGrid; 123747; 177.
DR   DIP; DIP-29849N; -.
DR   IntAct; Q96J02; 34.
DR   MINT; MINT-148272; -.
DR   STRING; 9606.ENSP00000363998; -.
DR   iPTMnet; Q96J02; -.
DR   PhosphoSitePlus; Q96J02; -.
DR   BioMuta; ITCH; -.
DR   DMDM; 37537897; -.
DR   EPD; Q96J02; -.
DR   MaxQB; Q96J02; -.
DR   PaxDb; Q96J02; -.
DR   PeptideAtlas; Q96J02; -.
DR   PRIDE; Q96J02; -.
DR   Ensembl; ENST00000262650; ENSP00000262650; ENSG00000078747. [Q96J02-1]
DR   Ensembl; ENST00000374864; ENSP00000363998; ENSG00000078747. [Q96J02-2]
DR   Ensembl; ENST00000535650; ENSP00000445608; ENSG00000283472. [Q96J02-3]
DR   GeneID; 83737; -.
DR   KEGG; hsa:83737; -.
DR   UCSC; uc002xak.3; human. [Q96J02-1]
DR   CTD; 83737; -.
DR   DisGeNET; 83737; -.
DR   GeneCards; ENSG00000283472; -.
DR   GeneCards; ITCH; -.
DR   H-InvDB; HIX0015745; -.
DR   HGNC; HGNC:13890; ITCH.
DR   HPA; HPA021126; -.
DR   HPA; HPA049032; -.
DR   MalaCards; ENSG00000283472; -.
DR   MalaCards; ITCH; -.
DR   MIM; 606409; gene.
DR   MIM; 613385; phenotype.
DR   neXtProt; NX_Q96J02; -.
DR   OpenTargets; ENSG00000078747; -.
DR   Orphanet; 228426; Syndromic multisystem autoimmune disease due to Itch deficiency.
DR   PharmGKB; PA29934; -.
DR   eggNOG; KOG0940; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000118966; -.
DR   HOVERGEN; HBG004134; -.
DR   InParanoid; Q96J02; -.
DR   KO; K05632; -.
DR   OMA; SICLDGL; -.
DR   OrthoDB; EOG091G0SS8; -.
DR   PhylomeDB; Q96J02; -.
DR   TreeFam; TF323658; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-5610780; Degradation of GLI1 by the proteasome.
DR   Reactome; R-HSA-5632684; Hedgehog 'on' state.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q96J02; -.
DR   SIGNOR; Q96J02; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; ITCH; human.
DR   EvolutionaryTrace; Q96J02; -.
DR   GenomeRNAi; 83737; -.
DR   PRO; PR:Q96J02; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000078747; -.
DR   CleanEx; HS_ITCH; -.
DR   Genevisible; Q96J02; HS.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045236; F:CXCR chemokine receptor binding; IPI:UniProtKB.
DR   GO; GO:0016874; F:ligase activity; IEA:Ensembl.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0019787; F:ubiquitin-like protein transferase activity; TAS:Reactome.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0046642; P:negative regulation of alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050687; P:negative regulation of defense response to virus; IMP:UniProtKB.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; ISS:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0002669; P:positive regulation of T cell anergy; IEA:Ensembl.
DR   GO; GO:0035519; P:protein K29-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0090085; P:regulation of protein deubiquitination; ISS:BHF-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:MGI.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00397; WW; 4.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00456; WW; 4.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51045; SSF51045; 4.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 4.
DR   PROSITE; PS50020; WW_DOMAIN_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Antiviral defense;
KW   Apoptosis; Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Host-virus interaction; Immunity;
KW   Innate immunity; Membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    903       E3 ubiquitin-protein ligase Itchy
FT                                homolog.
FT                                /FTId=PRO_0000120317.
FT   DOMAIN        5     99       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      326    359       WW 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      358    391       WW 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      438    471       WW 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      478    511       WW 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      569    903       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   REGION      395    471       Required for interaction with FYN.
FT                                {ECO:0000269|PubMed:16387660}.
FT   REGION      574    583       MAP kinase docking site. {ECO:0000250}.
FT   COMPBIAS    252    267       Arg/Pro-rich (PRR domain).
FT   ACT_SITE    871    871       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00104}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     240    240       Phosphoserine; by MAPK8. {ECO:0000250}.
FT   MOD_RES     263    263       Phosphothreonine; by MAPK8.
FT                                {ECO:0000250}.
FT   MOD_RES     273    273       Phosphoserine; by MAPK8. {ECO:0000250}.
FT   MOD_RES     385    385       Phosphothreonine; by SGK3.
FT                                {ECO:0000269|PubMed:16888620}.
FT   MOD_RES     420    420       Phosphotyrosine; by FYN.
FT                                {ECO:0000269|PubMed:16387660}.
FT   MOD_RES     450    450       Phosphoserine; by SGK3.
FT                                {ECO:0000269|PubMed:16888620}.
FT   VAR_SEQ       1    110       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044732.
FT   VAR_SEQ     159    200       NGVSLCLPRLECNSAISAHCNLCLPGLSDSPISASRVAGFT
FT                                G -> S (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:11318614,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9647693,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_008451.
FT   MUTAGEN     343    343       Y->F: No effect on phosphorylation on T-
FT                                cell stimulation nor in the presence of
FT                                FYN. {ECO:0000269|PubMed:16387660}.
FT   MUTAGEN     420    420       Y->F: Greatly reduced phosphorylation on
FT                                T-cell stimulation and in the presence of
FT                                FYN. Increased ITCH-mediated Ub
FT                                conjugation and degradation of JUNB.
FT                                {ECO:0000269|PubMed:16387660}.
FT   MUTAGEN     455    455       Y->F: No effect on phosphorylation on T-
FT                                cell stimulation nor in the presence of
FT                                FYN. {ECO:0000269|PubMed:16387660}.
FT   MUTAGEN     871    871       C->A: Loss of ubiquitin protein ligase
FT                                activity. Results in altered endosomal
FT                                sorting and reduced degradation of CXCR4.
FT                                Unable to inhibit MAVS-induced activation
FT                                of INFB. {ECO:0000269|PubMed:11046148,
FT                                ECO:0000269|PubMed:14602072,
FT                                ECO:0000269|PubMed:19881509}.
FT   CONFLICT    297    297       T -> I (in Ref. 3; BAG64996).
FT                                {ECO:0000305}.
FT   STRAND       18     29       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       41     47       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       50     53       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       64     73       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       78     85       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       88     90       {ECO:0000244|PDB:2NQ3}.
FT   STRAND       93    101       {ECO:0000244|PDB:2NQ3}.
FT   HELIX       102    108       {ECO:0000244|PDB:2NQ3}.
FT   TURN        109    111       {ECO:0000244|PDB:2NQ3}.
FT   STRAND      112    126       {ECO:0000244|PDB:2NQ3}.
FT   STRAND      130    143       {ECO:0000244|PDB:2NQ3}.
FT   STRAND      332    336       {ECO:0000244|PDB:2DMV}.
FT   STRAND      342    346       {ECO:0000244|PDB:2DMV}.
FT   TURN        347    349       {ECO:0000244|PDB:2DMV}.
FT   STRAND      352    355       {ECO:0000244|PDB:2DMV}.
FT   STRAND      365    368       {ECO:0000244|PDB:2KYK}.
FT   STRAND      374    377       {ECO:0000244|PDB:2KYK}.
FT   STRAND      379    381       {ECO:0000244|PDB:2KYK}.
FT   STRAND      444    448       {ECO:0000244|PDB:5CQ2}.
FT   STRAND      454    458       {ECO:0000244|PDB:5CQ2}.
FT   TURN        459    462       {ECO:0000244|PDB:5CQ2}.
FT   STRAND      463    467       {ECO:0000244|PDB:5CQ2}.
FT   HELIX       469    471       {ECO:0000244|PDB:5DWS}.
FT   STRAND      484    488       {ECO:0000244|PDB:5CQ2}.
FT   STRAND      494    498       {ECO:0000244|PDB:5CQ2}.
FT   TURN        499    502       {ECO:0000244|PDB:5CQ2}.
FT   STRAND      503    507       {ECO:0000244|PDB:5CQ2}.
FT   TURN        509    511       {ECO:0000244|PDB:5CQ2}.
FT   HELIX       528    539       {ECO:0000244|PDB:3TUG}.
FT   TURN        540    542       {ECO:0000244|PDB:3TUG}.
FT   STRAND      545    551       {ECO:0000244|PDB:3TUG}.
FT   STRAND      554    556       {ECO:0000244|PDB:3TUG}.
FT   HELIX       557    567       {ECO:0000244|PDB:3TUG}.
FT   HELIX       572    574       {ECO:0000244|PDB:3TUG}.
FT   STRAND      575    580       {ECO:0000244|PDB:3TUG}.
FT   HELIX       589    603       {ECO:0000244|PDB:3TUG}.
FT   TURN        607    609       {ECO:0000244|PDB:3TUG}.
FT   STRAND      611    614       {ECO:0000244|PDB:3TUG}.
FT   STRAND      621    624       {ECO:0000244|PDB:3TUG}.
FT   HELIX       626    630       {ECO:0000244|PDB:3TUG}.
FT   HELIX       634    650       {ECO:0000244|PDB:3TUG}.
FT   HELIX       661    667       {ECO:0000244|PDB:3TUG}.
FT   HELIX       675    677       {ECO:0000244|PDB:3TUG}.
FT   TURN        678    680       {ECO:0000244|PDB:3TUG}.
FT   HELIX       682    692       {ECO:0000244|PDB:3TUG}.
FT   HELIX       696    699       {ECO:0000244|PDB:5C7M}.
FT   STRAND      704    709       {ECO:0000244|PDB:5C7M}.
FT   STRAND      716    721       {ECO:0000244|PDB:5C7M}.
FT   HELIX       724    726       {ECO:0000244|PDB:5C7M}.
FT   TURN        731    733       {ECO:0000244|PDB:5C7M}.
FT   HELIX       735    747       {ECO:0000244|PDB:3TUG}.
FT   HELIX       751    764       {ECO:0000244|PDB:3TUG}.
FT   HELIX       767    770       {ECO:0000244|PDB:3TUG}.
FT   HELIX       775    783       {ECO:0000244|PDB:3TUG}.
FT   HELIX       790    795       {ECO:0000244|PDB:3TUG}.
FT   STRAND      798    801       {ECO:0000244|PDB:3TUG}.
FT   HELIX       807    818       {ECO:0000244|PDB:3TUG}.
FT   HELIX       821    832       {ECO:0000244|PDB:3TUG}.
FT   HELIX       842    844       {ECO:0000244|PDB:3TUG}.
FT   STRAND      848    851       {ECO:0000244|PDB:3TUG}.
FT   STRAND      855    858       {ECO:0000244|PDB:3TUG}.
FT   STRAND      867    869       {ECO:0000244|PDB:3TUG}.
FT   HELIX       870    872       {ECO:0000244|PDB:3TUG}.
FT   STRAND      874    877       {ECO:0000244|PDB:3TUG}.
FT   HELIX       883    895       {ECO:0000244|PDB:3TUG}.
SQ   SEQUENCE   903 AA;  102803 MW;  6777A2043C7B67BC CRC64;
     MSDSGSQLGS MGSLTMKSQL QITVISAKLK ENKKNWFGPS PYVEVTVDGQ SKKTEKCNNT
     NSPKWKQPLT VIVTPVSKLH FRVWSHQTLK SDVLLGTAAL DIYETLKSNN MKLEEVVVTL
     QLGGDKEPTE TIGDLSICLD GLQLESEVVT NGETTCSENG VSLCLPRLEC NSAISAHCNL
     CLPGLSDSPI SASRVAGFTG ASQNDDGSRS KDETRVSTNG SDDPEDAGAG ENRRVSGNNS
     PSLSNGGFKP SRPPRPSRPP PPTPRRPASV NGSPSATSES DGSSTGSLPP TNTNTNTSEG
     ATSGLIIPLT ISGGSGPRPL NPVTQAPLPP GWEQRVDQHG RVYYVDHVEK RTTWDRPEPL
     PPGWERRVDN MGRIYYVDHF TRTTTWQRPT LESVRNYEQW QLQRSQLQGA MQQFNQRFIY
     GNQDLFATSQ SKEFDPLGPL PPGWEKRTDS NGRVYFVNHN TRITQWEDPR SQGQLNEKPL
     PEGWEMRFTV DGIPYFVDHN RRTTTYIDPR TGKSALDNGP QIAYVRDFKA KVQYFRFWCQ
     QLAMPQHIKI TVTRKTLFED SFQQIMSFSP QDLRRRLWVI FPGEEGLDYG GVAREWFFLL
     SHEVLNPMYC LFEYAGKDNY CLQINPASYI NPDHLKYFRF IGRFIAMALF HGKFIDTGFS
     LPFYKRILNK PVGLKDLESI DPEFYNSLIW VKENNIEECD LEMYFSVDKE ILGEIKSHDL
     KPNGGNILVT EENKEEYIRM VAEWRLSRGV EEQTQAFFEG FNEILPQQYL QYFDAKELEV
     LLCGMQEIDL NDWQRHAIYR HYARTSKQIM WFWQFVKEID NEKRMRLLQF VTGTCRLPVG
     GFADLMGSNG PQKFCIEKVG KENWLPRSHT CFNRLDLPPY KSYEQLKEKL LFAIEETEGF
     GQE
//
